TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02656641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Client Feedback
Description: Clients complete rating scales before each therapy session. The therapist then views these results and discusses treatment progress with the client during the session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Self Feedback
Description: Clients complete rating scales before each therapy session. Progress is not reviewed with the therapist.
Study: NCT00006489

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy
Description: Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy
Description: Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Daily dosing 100 mg for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Daily dosing 100 mg for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill Placebo daily dosing 24 weeks
Study: NCT03255343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMDENDRIM
Description: In situ and intra tumoral injection of non removal nanodevice IMDENDRIM
Study: NCT02201537

Intervention type: DEVICE
Group type: OTHER
Intervention: renal echography
Description: Renal biopsy will be performed at 3 and 12 months.~The functional imaging examinations will be held as follows:~Step 1: the conventional Doppler ultrasound Step 2: ultrasound elastography Step 3: CEUS
Study: NCT03433664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 laser
Description: Fractional CO2 laser treatment using the DeepFX setting hand piece (Ultrapulse, Lumenis), performed under general anaesthetic at 4-6 week intervals. All treatments consisted of a single pass of 300Hz, 5% density and 50mJ energy with minimal overlapping
Study: NCT03183414

Intervention type: OTHER
Intervention: echocardiographic measurements
Description: echocardiographic parameters of the RV, measured with TEE and the right ventricular ejection fraction (thermodilution)
Study: NCT05888129

Intervention type: PROCEDURE
Intervention: surgery after neoadjuvant chemotherapy
Description: surgery after neoadjuvant chemotherapy

Intervention type: PROCEDURE
Intervention: surgery after neoadjuvant chemotherapy
Description: surgery after neoadjuvant chemotherapy
Study: NCT00647127

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine: 20microg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl: 25microg/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: '5microg/h' (not active drug, it is just called '5microg/h')
Study: NCT03169946

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RCT with CHX-MTZ,OFD
Description: Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement .
Study: NCT06030375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KAND567
Description: Continuous intravenous infusion for 6 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous intravenous infusion for 6 hours
Study: NCT00181714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate HCl (Concerta)
Description: OROS MPH will be openly prescribed to a maximum of 1.5 mg/kg/day (maximum 126 mg/day). Doses will be titrated according to clinical assessment of efficacy and tolerability.
Study: NCT00440362

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 2 doses at 2e8 IU given at T=0 and 8 weeks via the IM route

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 2 doses of 2e7 IU given at t=0 and 8 weeks via the SC route
Study: NCT01890408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: wound infusion ropivacaine
Description: Laparotomy Hepatic surgery :~Bolu of 10 ml de ropivacaine 0,2% + infusion with elastomeric pump with ropivacaine 0,2% at a 10ml/h during 48 hours.
Study: NCT00440362

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 2 doses at 2e8 IU given at T=0 and 8 weeks via the SC route

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose of placebo given at T=0 via the IM route

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose of placebo given at T=0 via the SC route
Study: NCT01835223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib (1mg)
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib (1.5mg)
Description: Given PO
Study: NCT00303485

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po monthly for 6 months
Study: NCT03169946

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RCT with CHX,OFD
Description: Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement.
Study: NCT03047109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: 30 patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: 30 patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
Study: NCT03448315

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: motor cortex stimulation (2 mA, 20 min for 4 sessions)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: motor cortex stimulation (2 mA, 20 min for 4 sessions)
Study: NCT04846725

Intervention type: OTHER
Intervention: Data collection
Description: Collect in medical records :~* Filter's retrieval rate~* Complications of vena cava filters~* Predictive factors of attempted inferior vena cava filters retrieval: age, the distance between the patient's home and the hospital, the indication or not given by the therapeutic medicine department, patients referred by external structures, patients whose filter was installed during the medical on-call period, the absence of a written request for filter placement, the presence of active neoplasia at the time of filter placement, a peri-surgical context.
Study: NCT03575884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen Time Reduction Curriculum
Description: Fit5Kids classroom curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices offered over 7-8 weeks in the Fall semester. The classroom component will be taught by bilingual (English/Spanish) research staff interventionists. Parent newsletters, goal setting, and text messages will be offered in English and Spanish per parent preference. There will also be two booster weeks of classroom activities, daily parent newsletters, goal setting, and daily text messages on screen time parenting practices offered during the booster weeks in the Spring semester. The lending library of resources for parents/children will be available throughout the entire school year.
Study: NCT00117559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Treatment
Description: Participants receive a 15-minute telephone call for 8 weeks
Study: NCT00113659

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Daily dose of ten to the tenth colony-forming units of Lactobacillus GG and 225 mg of inulin for the first 6 months of life.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of placebo supplement containing 325mg inulin for the first 6 month of life.
Study: NCT00253383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: counseling intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study: NCT02614911

Intervention type: OTHER
Intervention: Biological sampling
Description: Biological sampling including blood, feces, biopsies...

Intervention type: OTHER
Intervention: Biological sampling
Description: Biological sampling including blood, feces, biopsies...
Study: NCT03666078

Intervention type: PROCEDURE
Intervention: cesarean delivery
Description: women delivered by cesarean section

Intervention type: PROCEDURE
Intervention: cesarean delivery
Description: women delivered by cesarean section
Study: NCT03067805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Infidelity Condition

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sexual Infidelity Condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Infidelity Condition

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Emotional Infidelity Condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral Condition

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Player in Jealousy Condition

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Player in Jealousy Condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Player in Non-Jealousy Condition

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Player in Non-Jealousy Condition
Study: NCT02040610

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated Proton Therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated Proton Therapy
Study: NCT00440362

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo given at T=0 and 8 weeks via the IM route

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo given at T=0 and 8 weeks via the SC route
Study: NCT03055208

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: gamma knife radiosurgery (15 Gy to 50% isodose)
Description: Radiosurgery with a gamma knife resembles the application of a precisely focused, high single dose of ionizing irradiation.
Study: NCT01952821

Intervention type: OTHER
Intervention: Six-Minute Walk Test

Intervention type: OTHER
Intervention: 10-Meter Walk Test

Intervention type: OTHER
Intervention: 30-Second Chair Stand

Intervention type: OTHER
Intervention: Linear Analog Scale of Function

Intervention type: OTHER
Intervention: Modified Brief Fatigue Inventory

Intervention type: OTHER
Intervention: FACIT-Fatigue
Study: NCT01572012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron solution 4 mg single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron + Hylenex
Description: Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofran ODT
Description: Zofran ODT (8 mg) single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron solution
Description: Ondansetron solution (4 mg) single administration
Study: NCT03494764

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric oxygen (HBO) provides 100% oxygen at a pressure above atmospheric pressure (typically twice to three times standard sea level pressure (2.0-3.0 ATA)). This dramatically increases the amount of oxygen dissolved in blood plasma, which in turn increases oxygen delivery to tissues. This effect of hyperbaric oxygen is used clinically to treat acute hypoxia in crush injuries, severed limbs, and failing skin grafts

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric oxygen (HBO) provides 100% oxygen at a pressure above atmospheric pressure (typically twice to three times standard sea level pressure (2.0-3.0 ATA)). This dramatically increases the amount of oxygen dissolved in blood plasma, which in turn increases oxygen delivery to tissues. This effect of hyperbaric oxygen is used clinically to treat acute hypoxia in crush injuries, severed limbs, and failing skin grafts
Study: NCT01370499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Participants were to enter the study taking their current stable SSRI treatment dose and maintain the same dose throughout the study.
Study: NCT03641599

Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: echocardiographic assessment of the RV and LV systolic function

Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: echocardiographic assessment of the RV and LV systolic function

Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: echocardiographic assessment of the RV and LV systolic function
Study: NCT00771420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAM-3001
Description: A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAM-3001
Description: Dosed at 0.1mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAM-3001
Description: Dosed at 0.3mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAM-3001
Description: Dosed at 1.0 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAM-3001
Description: Dosed at 3.0 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAM-3001
Description: Dosed at 10 mg/kg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active: Placebo 5:1 for arms 2-6
Study: NCT04487275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLC901 or Placebo
Description: groups randomly assigned to receive either MLC901 or placebo capsules three times per day over 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MLC901 or Placebo
Description: groups randomly assigned to receive either MLC901 or placebo capsules three times per day over 6 months
Study: NCT01136759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel
Description: One applicator of tenofovir 1% gel administered vaginally for 7 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel
Description: One applicator of tenofovir 1% gel administered vaginally for 7 consecutive days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: One applicator of placebo gel administered vaginally for 7 consecutive days
Study: NCT03611907

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oocyte retrieval with only aspiration system SL1(Cook® Single Lumen)
Description: In this intervention a 17-Gauge needle is used to aspirate the follicles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oocyte retrieval with aspiration and flushing system DL1 (Cook® EchoTip® Double Lumen)
Description: In this intervention a 17-Gauge needle is used to aspirate follicle, and consequently a 1 mL flush is injected and aspirated twice for each punctured follicle
Study: NCT04227678

Intervention type: DRUG
Group type: OTHER
Intervention: Heparin
Description: an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours, starting 15 minutes before ingestion of liquid meal

Intervention type: DRUG
Group type: OTHER
Intervention: Heparin
Description: an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours, starting 15 minutes before ingestion of liquid meal

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: liquid meal
Description: low fat meal: (500 mL, 898 Kcal, 13% fat, 20.3% protein and 62.3% carbohydrates) will be ingested over 20 minutes

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: liquid meal
Description: low fat meal: (500 mL, 898 Kcal, 13% fat, 20.3% protein and 62.3% carbohydrates) will be ingested over 20 minutes

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: liquid meal
Description: low fat meal: (500 mL, 898 Kcal, 13% fat, 20.3% protein and 62.3% carbohydrates) will be ingested over 20 minutes
Study: NCT04529135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
Study: NCT00615199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: administration via oral route twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: administration via oral route twice daily
Study: NCT04227678

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: liquid meal
Description: low fat meal: (500 mL, 898 Kcal, 13% fat, 20.3% protein and 62.3% carbohydrates) will be ingested over 20 minutes
Study: NCT03110172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine Hydrochloride
Description: The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine Hydrochloride
Description: The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine Hydrochloride
Description: The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine Hydrochloride
Description: The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation
Study: NCT01791543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intramural Needle Ablation Catheter
Study: NCT00266331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reduced glutathione
Study: NCT00999453

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LDL-cholesterol
Description: This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LDL-cholesterol
Description: This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.